MedPath

Tamsulosin

Generic Name
Tamsulosin
Brand Names
Flomax, Jalyn
Drug Type
Small Molecule
Chemical Formula
C20H28N2O5S
CAS Number
106133-20-4
Unique Ingredient Identifier
G3P28OML5I
Background

Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication

Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions
Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
Clinical Trials
Related News

FDA Approves Gemtesa (Vibegron) for Overactive Bladder in Men with BPH

• The FDA has approved Gemtesa (vibegron) for men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia (BPH). • Gemtesa is the first and only beta-3 adrenergic receptor agonist approved for OAB in men being treated for BPH, addressing a significant unmet need. • Approval was based on a Phase 3 trial demonstrating significant reductions in micturition and urgency episodes compared to placebo. • Common adverse reactions in the trial included hypertension and urinary tract infections, with a similar rate of serious adverse events to placebo.

PARTIQoL Trial Assesses Proton Therapy vs. IMRT for Localized Prostate Cancer

• The PARTIQoL trial is a randomized phase III study comparing proton beam therapy to IMRT for localized prostate cancer, focusing on patient-reported outcomes. • The trial enrolled 450 patients across 29 centers, employing strategies to overcome accrual challenges, including patient-centric initiatives and insurance partnerships. • Preliminary data suggests that proton therapy may offer dosimetric advantages, potentially reducing side effects and second cancer risk, but rigorous data is still needed. • The study's primary endpoint is patient-reported bowel function at 24 months, with longer follow-up ongoing to assess the long-term impact on quality of life.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy